The Safety of Postmenopausal Testosterone Therapy

Maclaran, Kate; Panay, Nick

doi:10.2217/whe.12.11

Cited by 16 publications

(3 citation statements)

References 128 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Oral testosterone therapy increases triglycerides and low-density lipoprotein cholesterol and reduces high-density lipoprotein cholesterol. These adverse lipid effects have raised concern regarding safety [52]. In 967 surgically menopausal women who were also on estrogen replacement, transdermal testosterone therapy did not affect lipid profiles over 4 years of follow up [53].…”

Section: Treatmentsmentioning

confidence: 99%

Menopause and Sexuality

Thornton

Chervenak

Neal‐Perry

2015

Endocrinology and Metabolism Clinics of North America

View full text Add to dashboard Cite

Synopsis Sexuality is an important component in the lives of menopausal women. The addition of phosphodiesterase type 5 inhibitors for the treatment of male erectile dysfunction in combination with longer life expectancy has impacted attitudes and expectations to maintain sexual functioning. Despite the importance of sexual function in menopausal women, sexual dysfunction increases with age. Age-related decline in sexual function may significantly reduce quality of life, making recognition of sexual dysfunction by physicians important for getting menopausal women effective care. Sexual dysfunction can result from multiple etiologies including psychosocial factors, medication side effects, vulvovaginal atrophy, chronic illness, or hypoactive sexual desire disorder (HSDD). Discovering the etiology and identifying modifiable factors of the sexual function will help define appropriate treatment.

show abstract

Section: Treatmentsmentioning

confidence: 99%

Menopause and Sexuality

Thornton

Chervenak

Neal‐Perry

2015

Endocrinology and Metabolism Clinics of North America

View full text Add to dashboard Cite

show abstract

“…Giving testosterone via the transdermal route avoids first-pass metabolism in the liver and leads to more physiological and stable serum levels. 17 A systematic review and large meta-analysis of the safety of the transdermal patch showed that no changes in serum lipid profile, renal, liver function or blood cell indices were seen with transdermal testosterone. 18 Testosterone does not appear to stimulate the endometrium.…”

Section: Discussionmentioning

confidence: 99%

The testosterone prescribing practice of BMS menopause specialists

Scott¹,

Holloway

Rymer

et al. 2021

Post Reprod Health

View full text Add to dashboard Cite

The NICE Guidelines published in 2015 state that testosterone supplementation can be considered for menopausal women with low sexual desire if hormone replacement therapy alone is not effective. There is however, no detail on what to prescribe, how much to prescribe or whether monitoring is required. At the time of conception of this project, there was no national guideline or official advice from the British Menopause Society. We decided to ask menopause experts from around the UK to see if a consensus could be reached about good prescribing practice. The method and results as discussed below may be helpful in future recommendations and guidance.

show abstract

“…Transdermal testosterone does not appear to stimulate the endometrium [101][102][103] ; nor does it appear to increase mammographic breast density 95,104,105 or elevate breast cancer risk. 78,96,98 Because testosterone aromatizes to estradiol, there have been some concerns that it could have secondary stimulatory effects on the estrogen receptor.…”

Section: Breast and Endometriummentioning

confidence: 99%

Individual Benefits and Risks of Intravaginal Estrogen and Systemic Testosterone in the Management of Women in the Menopause, With a Discussion of Any Associated Risks for Cancer Development

Laing¹,

Newson²,

Simon

2022

Cancer J

View full text Add to dashboard Cite

Several formulations of intravaginal oestrogen are available for the treatment of genitourinary syndrome of menopause (GSM). These are safe and effective treatments for the symptoms of GSM. Licensed doses of intravaginal oestrogen do not elevate systemic estradiol levels above the normal postmenopausal range with long term use and there is no evidence of an increased risk of coronary heart disease, stroke, thromboembolism, colorectal cancer, endometrial cancer, breast cancer or breast cancer recurrence with their use. This should reassure both women and their healthcare professionals and should lead to more women receiving these localised, vaginally administered hormonal treatments. Available evidence also suggests a positive safety profile for transdermal testosterone treatment when delivered at physiological concentrations.

show abstract

The Safety of Postmenopausal Testosterone Therapy

Cited by 16 publications

References 128 publications

Menopause and Sexuality

Menopause and Sexuality

The testosterone prescribing practice of BMS menopause specialists

Individual Benefits and Risks of Intravaginal Estrogen and Systemic Testosterone in the Management of Women in the Menopause, With a Discussion of Any Associated Risks for Cancer Development

Contact Info

Product

Resources

About